Based on our cluster 2 findings (IL-6/STAT3 overexpression linked to fibrosis) and the established pro-fibrotic role of sustained STAT3 activation, we propose that targeted STAT3 inhibition holds specific therapeutic promise for cluster 2 patients with fibrostenotic CD. This evidence concerns the gene STAT3 and Cowden disease.